Systemic Lupus Erythematosus
Conditions
Brief summary
Systemic lupus erythematous (SLE) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course. The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the Reproductive years. In adults, the female to male ratio is 10- 15:1(1)( 2) Clinical features in individual patients can be quite variable and range from mild joint and skin involvement to severe, life-threatening internal organ disease. Constitutional symptoms, rash, mucosal ulcers, inflammatory polyarthritis, photosensitivity, and serositis are the most common clinical features of the disease. (3) (4) Anti-DFS70 antibodie) and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies , there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of antinuclear antibodies associated rheumatic diseases. (8) Anti-DFS70 antibodies were not associated with lupus nephritis development in Systemic lupus erythematosus patients but were associated with anti-dsDNA antibodies , proliferative lupus nephritis, and renal activity index . This suggests their potential to serve as a non-histological biomarker for lupus nephritis subclass and activity status. (8)
Interventions
blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients who fulfill the 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematous . (9) 2. Patients who is able to give informed consent to join the study. •
Exclusion criteria
\- \- Any patient with any collagen disease other than systemic lupus erythematous
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| antiDFS70 antibodies titre | 1 year | serve as a non-histological biomarker for lupus nephritis subclass and activity status. |
Countries
Egypt